Table 2.
Primary and Secondary outcomes of the meta-analyses.
| Subgroups | Outcome Index | Number. Of Studies | Statistical Method | Effect Estimate |
p-Value | Heterogeneity |
|---|---|---|---|---|---|---|
| Primary outcomes | ||||||
| Resected PC | ||||||
| PtCh for DDRm vs. without DDRm | OS | 5 | HR (IV, Random, 95% CI) | 0.85(0.64, 1.13) | p=0.27 | I2 = 65% |
| Non-PtCh for DDRm vs. without DDRm | OS | 3 | HR (IV, Fixed, 95% CI) | 0.87(0.37, 2.00) | p=0.74 | I2 = 0% |
| DDRm vs. without DDRm | OS | 9 | HR (IV, Random, 95% CI) | 0.82 (0.65, 1.03) | p=0.09 | I2 = 71% |
| Advanced PC | ||||||
| PtCh for DDRm vs. without DDRm | PFS | 4 | HR (IV, Fixed, 95% CI) | 0.41(0.30, 0.56) | p<0.00001 | I2 = 0% |
| PtCh for DDRm vs. without DDRm | OS | 5 | HR (IV, Random, 95% CI) | 0.48(0.32, 0.71) | p=0.0002 | I2 = 59% |
| Non-PtCh for DDRm vs. without DDRm | OS | 2 | HR (IV, Random, 95% CI) | 0.95(0.33, 2.71) | p=0.92 | I2 = 78% |
| DDRm vs. without DDRm | OS | 6 | HR (IV, Random, 95% CI) | 0.63 (0.47,0.87) | p=0.004 | I2 = 66% |
| Secondary outcomes for advanced PC | ||||||
| First-line PtCh for DDRm vs. without DDRm | PFS | 3 | HR (IV, Random, 95% CI) | 0.44 (0.32, 0.59) | p<0.00001 | I2 = 0% |
| Second or later line PtCh for DDRm vs. without DDRm | PFS | 3 | HR (IV, Random, 95% CI) | 0.98 (0.51, 1.87) | p=0.95 | I2 = 83% |
| ATM/ATR mutations vs. wild control group | OS | 2 | HR (IV, Random, 95% CI) | 0.46 (0.14, 1.52) | p=0.20 | I2 = 68% |
HR, hazard ratio; 95%CI, 95% certification interval; DDRm, DNA-damage-repair mutations; Fixed/Random, fixed/random-effects model; PFS, progression-free survival; PC, pancreatic cancer; PtCh, platinum-based therapy; First-line, first-line PtCh; OS, overall survival; mOS, median OS.